J Infection:治疗持续性念珠菌血症:棘白菌素pk氟康唑

2018-09-28 吴星 环球医学网

2018年9月,台湾学者在《J Infect》发表了一项时间依赖分析,考察了棘白菌素vs氟康唑治疗持续性念珠菌血症的有效性。

2018年9月,台湾学者在《J Infect》发表了一项时间依赖分析,考察了棘白菌素vs氟康唑治疗持续性念珠菌血症的有效性。

目的:棘白菌素具有杀真菌作用,比氟康唑在对念珠菌生物膜更具活性。这是念珠菌持续存在的已知重要机制。然而,棘白菌素治疗持续性念珠菌血症有效性的证据有限。

方法:2011年3月~2016年2月,研究者前瞻性观察了持续性念珠菌血症成年患者。持续性念珠菌血症的定义为从血培养中分离相同的念珠菌种≥5天。研究者使用时间依赖分析,评估针对性治疗对指数日期(收集第二个阳性血液培养的日期)以来30天时真菌学根除和总生存率的影响。

结果:研究者筛查了1162个念珠菌血症发作。纳入的196个非重复患者中,64人接受棘白菌素,132人接受氟康唑作为他们各自的指数日期后首个针对性治疗。真菌学根除率和总生存率分别为67.3%和55.6%。与真菌学根除相关的因素包括接受棘白菌素作为针对性治疗、充分的来源控制、未接受肠外高营养。与总生存率相关的因素为APACHE II、未接受糖皮质激素、接受血管或腹部手术。

结论:在持续性念珠菌血症患者中,棘白菌素比氟康唑在实现真菌学根除上更有效。

原始出处:
Lin KY, Chen PY, Chuang YC,et al.Effectiveness of echinocandins versus fluconazole for treatment of persistent candidemia: A time-dependent analysis.J Infect. 2018 Sep;77(3):242-248. doi: 10.1016/j.jinf.2018.05.011. Epub 2018 Jun 19.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922581, encodeId=fe59192258179, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 05 13:15:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670598, encodeId=fdba16e059897, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun May 26 05:15:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303951, encodeId=79811303951fa, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524441, encodeId=318e152444166, content=<a href='/topic/show?id=f0f998396d' target=_blank style='color:#2F92EE;'>#Infection#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9839, encryptionId=f0f998396d, topicName=Infection)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e211601877, createdName=lidong44, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603300, encodeId=52131603300f8, content=<a href='/topic/show?id=ba9a6392545' target=_blank style='color:#2F92EE;'>#氟康唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63925, encryptionId=ba9a6392545, topicName=氟康唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68c19021189, createdName=yhj-time, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922581, encodeId=fe59192258179, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 05 13:15:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670598, encodeId=fdba16e059897, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun May 26 05:15:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303951, encodeId=79811303951fa, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524441, encodeId=318e152444166, content=<a href='/topic/show?id=f0f998396d' target=_blank style='color:#2F92EE;'>#Infection#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9839, encryptionId=f0f998396d, topicName=Infection)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e211601877, createdName=lidong44, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603300, encodeId=52131603300f8, content=<a href='/topic/show?id=ba9a6392545' target=_blank style='color:#2F92EE;'>#氟康唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63925, encryptionId=ba9a6392545, topicName=氟康唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68c19021189, createdName=yhj-time, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1922581, encodeId=fe59192258179, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 05 13:15:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670598, encodeId=fdba16e059897, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun May 26 05:15:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303951, encodeId=79811303951fa, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524441, encodeId=318e152444166, content=<a href='/topic/show?id=f0f998396d' target=_blank style='color:#2F92EE;'>#Infection#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9839, encryptionId=f0f998396d, topicName=Infection)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e211601877, createdName=lidong44, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603300, encodeId=52131603300f8, content=<a href='/topic/show?id=ba9a6392545' target=_blank style='color:#2F92EE;'>#氟康唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63925, encryptionId=ba9a6392545, topicName=氟康唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68c19021189, createdName=yhj-time, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922581, encodeId=fe59192258179, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 05 13:15:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670598, encodeId=fdba16e059897, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun May 26 05:15:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303951, encodeId=79811303951fa, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524441, encodeId=318e152444166, content=<a href='/topic/show?id=f0f998396d' target=_blank style='color:#2F92EE;'>#Infection#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9839, encryptionId=f0f998396d, topicName=Infection)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e211601877, createdName=lidong44, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603300, encodeId=52131603300f8, content=<a href='/topic/show?id=ba9a6392545' target=_blank style='color:#2F92EE;'>#氟康唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63925, encryptionId=ba9a6392545, topicName=氟康唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68c19021189, createdName=yhj-time, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1922581, encodeId=fe59192258179, content=<a href='/topic/show?id=3f3156324ff' target=_blank style='color:#2F92EE;'>#持续性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56324, encryptionId=3f3156324ff, topicName=持续性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Wed Dec 05 13:15:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670598, encodeId=fdba16e059897, content=<a href='/topic/show?id=c0425209338' target=_blank style='color:#2F92EE;'>#念珠菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52093, encryptionId=c0425209338, topicName=念珠菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3be826737448, createdName=tigerlr107, createdTime=Sun May 26 05:15:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1303951, encodeId=79811303951fa, content=<a href='/topic/show?id=d1a0880e7c8' target=_blank style='color:#2F92EE;'>#菌血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88077, encryptionId=d1a0880e7c8, topicName=菌血症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5bc315, createdName=Tommy1949, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524441, encodeId=318e152444166, content=<a href='/topic/show?id=f0f998396d' target=_blank style='color:#2F92EE;'>#Infection#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9839, encryptionId=f0f998396d, topicName=Infection)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e211601877, createdName=lidong44, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603300, encodeId=52131603300f8, content=<a href='/topic/show?id=ba9a6392545' target=_blank style='color:#2F92EE;'>#氟康唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63925, encryptionId=ba9a6392545, topicName=氟康唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d68c19021189, createdName=yhj-time, createdTime=Sun Sep 30 04:15:00 CST 2018, time=2018-09-30, status=1, ipAttribution=)]

相关资讯

JAMA:对于持续性哮喘患者,LAMA 是ICS的得力助手吗?

2018年4月,发表在《JAMA》的一项由美国科学家进行的系统评价和Meta分析,考察了未控制的持续性哮喘患者中,吸入性糖皮质激素(ICS)和长效毒蕈碱受体拮抗剂(LAMA)与哮喘控制的相关性。

Retin Cases Brief Rep:患有高度近视的患者出现持续性盘状黄斑病变

宾夕法尼亚大学Perelman医学院Scheie眼科研究所眼科的Kolomeyer AM近日在Retin Cases Brief Rep发表了一篇文章,他们描述了一例高度近视患者持续性盘状黄斑病变的病例。

刷存在感!这个患者也需植入起搏器?!

一度房室传导阻滞多见于健康人,尤其是在60岁以上的老年人,一般也无重要的临床意义,多是建议定期随访,与它的老大哥三度房室传导阻滞相比,它可算是一个小透明。但是这个小透明有时也会怒刷自己的存在感。

J Rheumatol:纤维肌痛患者药物治疗的依从性和持续性

这项研究清楚地表明在FM患者中,在诊断后的一年中治疗的持续性和依从性很低。

Atherosclerosis:维生素D能否改善他汀治疗的依从性和持续性?

长期使用他汀会增加生存率。但是,其依从性和持续性是一种挑战,并会影响他汀治疗的成功与否。2018年4月,发表在《Atherosclerosis》的一项随机、双盲、安慰剂对照ViDA研究的二次分析调查了维生素D补充对长期他汀治疗依从性和持续性的影响。

Rheumatology:TNF抑制剂治疗持续性oJIA患者有效

持续性少关节型幼年特发性关节炎(oJIA)通常在6岁前起病,女性多见,表现为膝关节和踝关节为主的非对称性关节炎。其合并葡萄膜炎及抗核抗体(ANA)阳性者多见。TNF抑制剂在说明书中并没有治疗持续性oJIA的适应症,但在临床工作中,针对这一疾病,医师并非均按照说明书用药。为评估oJIA患者使用TNF抑制剂的有效性,来自荷兰Erasmus MC索菲亚儿童医院儿童风湿病科的Janneke Anink等人